EUVIMEDEUVIMED entdecken
Crossref

Comorbidities and comedication in the treatment of functional gastrointestinal disorders – pharmacoepidemiological data on a herbal medicinal product

S Göttlich, B R Vinson, O Kelber, E Raskopf, K Shah, R Mösges, K Nieber, K Kraft

Planta Medica · 01.03.2026 · 92 (03) · 403-404

DOI: 10.1055/s-0045-1815417 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Planta Medica, erschienen am 01.03.2026. Verfasst von S Göttlich und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Herbal Medicinal products (HMPs) are key in the treatment of Disorders of the Gut Brain Interaction( DGBI), which are often accompanied by comorbidities and also respective comedication. To assess these, real world data (RWD) for a leading medicinal product in the field, STW 5 [ 2 ] [ 3 ] were captured from the PhytoVIS study [ 1 ], where RWD on the usage of HMPs from more than 20,000 patients were collected. The respective data sets were evaluated based on the ATC code. From the 1515 patients identified, 32.8% reported one or more comorbidities, most frequently hypertension (11.9%), metabolic disorders (9.0%), and back pain (3.6%). 56% reported no comedication, 28.1% taking one and 15.9% taking up to nine additional medicines ([ Fig. 1 ]). 45.6% of female and 39.9% of male patients, resp. 76.3% of those over 65 years of age reported co-medication. The ATC code C (cardiovascular system) accounted for 26.3%, A (alimentary system and metabolism) for 20.0%, H (systemic hormone preparations excluding sex hormones and insulin) for 12.8%, and N (nervous system) for 8.4% of the co-medication, to name the four most common ATC codes. Thyroid hormones (17.9%) and low-dose ASS (4.0%) were among the medicines most frequently mentioned. There was no evidence of interactions between STW 5 and the co-medication. Approximately onethird of the patients had a comorbidity, and almost half were receiving co-medication in addition to treatment with STW 5. The data thus provide a unique pharmacoepidemiological overview for a large cohort of patients with functional gastrointestinal diseases [ 4 ]. Fig. 1 Patients with comedication (in%) Publication History Article published online: 05 March 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Zitieren

APA

Göttlich, S., Vinson, B. R., Kelber, O., Raskopf, E., Shah, K., Mösges, R., Nieber, K., & Kraft, K. (2026). Comorbidities and comedication in the treatment of functional gastrointestinal disorders – pharmacoepidemiological data on a herbal medicinal product. Planta Medica, 92(03), 403-404. https://doi.org/10.1055/s-0045-1815417

Vancouver

Göttlich S, Vinson BR, Kelber O, Raskopf E, Shah K, Mösges R, et al. Comorbidities and comedication in the treatment of functional gastrointestinal disorders – pharmacoepidemiological data on a herbal medicinal product. Planta Medica. 2026;92(03):403-404. doi:10.1055/s-0045-1815417

BibTeX
@article{Gttlich2026,
  author = {Göttlich, S and Vinson, B R and Kelber, O and Raskopf, E and Shah, K and Mösges, R and Nieber, K and Kraft, K},
  title = {Comorbidities and comedication in the treatment of functional gastrointestinal disorders – pharmacoepidemiological data on a herbal medicinal product},
  journal = {Planta Medica},
  year = {2026},
  volume = {92},
  number = {03},
  pages = {403--404},
  doi = {10.1055/s-0045-1815417}
}
Kostenlos starten →